40 results about "Whole cell vaccine" patented technology

A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing Staphylococcus infection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.

The invention provides a fusion protein, a recombinant vector, recombinant dendritic cells for transmembrane expression of novel coronavirus antigen S2, and application thereof, and belongs to the technical field of whole-cell vaccines. The fusion protein comprises a CD4 signal peptide, a novel coronavirus antigen S2 protein, a Flag tag sequence and a CD4 transmembrane domain which are linked in sequence; According to the invention, transmembrane cell expression is independently carried out on S2, ADE risks possibly caused by other S protein epitopes are avoided. The cell vaccine constructed by the fusion protein provided by the invention can induce higher neutralizing antibody titer in a mouse body.

Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.

The invention provides a swine mycoplasma pneumonia vaccine composition, the vaccine composition includes swine pneumonia mycoplasma whole cell antigen and an immunogenic protein, and also comprises a veterinary-medicine-acceptable carrier, wherein the immunogenic protein comprises at least one of XylF and P78 proteins. The present invention also discloses the application of the vaccine composition in preparing of medicines for preventing and / or treating swine mycoplasma pneumonia. The content of the whole cell antigen and the immunogenic protein of the vaccine composition is decreased significantly compared with that of single use of a whole cell vaccine or a subunit vaccine for immunization, and immune effect is enhanced; protein part can be recombinationally expressed by means of genetic engineering in quantity, short time is taken, and the swine mycoplasma pneumonia vaccine composition can also be convenient for mass production. In addition, when an animal is immunized with the vaccine composition, the immune effects of the vaccine composition on the swine mycoplasma pneumonia antigen contained in the vaccine composition and other antigens are not affected.

A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.

An objective of the present invention is to provide a whole-cell bacterial vaccine composition for preventing whooping cough caused by Bordetella parapertussis, comprising whole cells, whole-cell homogenate, or cell lysate of B. parapertussis as an immunogen, and methods for producing them.

A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.

The invention provides a fusion protein, a recombinant vector, a recombinant dendritic cell and its application for transmembrane expression of novel coronavirus antigen S2, belonging to the technical field of whole cell vaccines. The fusion protein includes CD4 signal peptide linked in sequence , novel coronavirus antigen S2 protein, Flag tag sequence and CD4 transmembrane domain; the present invention expresses S2 alone across the membrane, avoiding the risk of ADE that may be caused by other S protein epitopes, and the fusion protein construction provided by the present invention The cellular vaccine can induce higher neutralizing antibody titers in mice.

The present invention provides immunogenic compositions having an inactivated, whole-cell S. pneumoniae, multiplex immunity-inducing fraction and methods of making immunogenic compositions by The immunogenic composition is prepared by selectively lysing a whole-cell bacterial preparation in such a way that the soluble fraction that primarily induces an antibody response and the cellular fraction that primarily induces an antibody-independent response are retained in the immunogenic composition.

The present invention relates to a radiation-resistant lung cancer whole-cell vaccine and its preparation method and application. Specifically, the present invention establishes a radiation-resistant lung cancer cell line with significantly improved radiation resistance. The preservation number is CCTCC C201537. The cell line is used to A lung cancer whole-cell vaccine was prepared, and animal experiments confirmed that the lung cancer whole-cell vaccine had the effects of significantly inhibiting the growth of mouse lung cancer tumors, promoting apoptosis of transplanted tumor cells, and reducing the expression of PDL-1 protein in immune escape of transplanted tumors, and combined with CpG ODN The anti-tumor effect is more significant, and the tumors of some mice completely disappear, and a durable and specific anti-tumor effect is obtained. The invention provides new ideas and methods for the treatment of lung cancer and the prevention of postoperative metastasis and recurrence.

Vibrio vulnificus can cause infections in aquaculture-raised fish and is considered an opportunistic human pathogen. We isolated V. vulnificus from diseased hybrid tilapia (Oreochromis niloticus X O. aureus) cultured in a North American water reuse aquaculture facility. We have characterized the isolate using biochemical and molecular methods, developed a disease infection model, and determined that formalin-inactivated whole-cell vaccine provides protection against V. vulnificus. The V. vulnificus isolate was determined to be biotype 1, 16S rRNA type B, vcg type C, and vvhA type 2. Fish vaccinated with the formalin-inactivated whole-cell vaccine responded to vaccination as measured by agglutinating antibody titer. In two separate trials, vaccinated tilapia exhibited relative percent survival of 73 and 60% following challenge with the homologous isolate. In additional trials, vaccinated tilapia exhibited survival values of up to 87.5% following challenge with a heterologous isolate. Use of a mineral oil adjuvant enhanced protection.

The invention belongs to the technical field of cellular immunotherapy, and specifically relates to a hepatitis B virus X protein (HBx) gene modified liver-cancer-inhibiting whole-cell vaccine. The invention aims at solving a technical problem of providing a novel gene-modified liver-cancer-inhibiting whole-cell vaccine which can be used for treating HBV-related liver cancer. The invention provides an HBx-modified liver-cancer-inhibiting whole-cell vaccine. The active components of the vaccine comprise liver cancer cells modified by liver cancer antigen gene, wherein the liver cancer antigen gene is HBx. The invention also provides a preparation method of the liver-cancer-inhibiting whole-cell vaccine. The liver-cancer-inhibiting whole-cell vaccine provided by the invention can be used in targeted killing of HBx-positive liver cancer cells, and shows good liver-cancer-inhibiting effect.